Will offer mRNA cGMP Production from Master Cell Bank to Drug Product Made Possible with Precision Nanosystems and Cytiva

Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from Master Cell Bank through to Drug Product.  This new capability will support the production of therapeutic-scale clinical and commercial-stage mRNA therapies for cancers and genetic diseases, and clinical-stage vaccines for infectious diseases.

Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, launches Eureca-V™ Nuclease, the wild-type MAD7® CRISPR Type-V nuclease, licensed from Inscripta®, at Research Grade today with GMP to follow.

On the pathway to GMP manufacturing in support of clinical trials, multiple technology transfers may correlate to an increase in complexity and risk to both product and timeline. The hand-off of new technologies, protocols, and materials can lead to delays or project failures.

Michael Chambers, the founding CEO of Aldevron, has been elected to the board of directors for the Whitehead Institute at the Massachusetts Institute of Technology.

Developing new CRISPR/Cas9-based genome editing tools will enhance innovative therapeutic products and the pathway to clinical programs. However, current obstacles in genome editing include high error rates, toxicity from production impurities, and strict regulatory concerns.

Thursday, November 3, 2022

8am PT, 11 am ET, 17:00 CET

Optimizing gene payload begins with plasmid design, and Nanoplasmids^TM provide several advantages over traditional plasmids. That’s the focus of our latest webinar, done in collaboration with Phacilitate, as a panel of Aldevron experts discuss the unique opportunities associated with using nanoplasmids.

October 6, 2022
11 a.m. – Noon, Eastern Time (10 -11 a.m., CT)

August 9
12:00 pm - 1:00 pm EDT

The Nanoplasmid™ vector is a high-performance <500 bp antibiotic-free bacterial backbone that, by combining the best attributes of plasmid and minicircle vectors, is designed to replace antiquated bacterial backbones that have for decades been the industry standard. The Nanoplasmid backbone is engineered to reduce plasmid associated innate immune activation which is ubiquitously associated with plasmid vectors; this translates to much lower observed toxicity and vector inactivation during primary cell transfection resulting in superior performance compared to plasmid and/or minicircle vectors with a broad range of gene and cell therapy products. This webinar will provide an overview of the Nanoplasmid technology and highlight the benefits in a variety of applications, relying on data from published studies.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

A partnership between two CRISPR pioneers will provide the global scientific community with GMP MAD7™ Nuclease

Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta®, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron a license to manufacture and commercialize Eureca-V™ Nuclease, the wild-type MAD7™ CRISPR Type-V nuclease.

March 22, 2022
8 am PT, 11 am ET, 16:00 CET

Watch On Demand

Acquisition combines Aldevron's leadership in GMP manufacturing with Nature Tech's portfolio of proprietary technologies.

Aldevron has acquired Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include Nanoplasmid^TM, a proprietary vector construct that improves the safety and performance of plasmids and biologics. Aldevron and NTC have complementary service offerings and pairing Aldevron's world-class manufacturing capabilities with NTC's innovative solutions will further support our clients and the patients they serve.

For more information about Nature Technology Corporation's full suite of offerings, visit www.natx.com

To get started now, complete the form, and a client relations representative will be in contact very soon.